Longtime Alzheimer’s physician and expert Oscar Lopez has joined the Alzheimer’s Association board of directors. The news marks the first time a Pittsburgh-based scientist and researcher will be on the board.

Lopez is director of the University of Pittsburgh Alzheimer’s Disease Research Center, chief of the cognitive and behavioral neurology division and a neurology professor at Pitt School of Medicine. He also is the founder of the Brain Training and Exercise (BRiTE) Wellness Program and chairs the Medical and Scientific Advisory Board at the Alzheimer’s Association, which provides scientific guidance to the national nonprofit.

Alzheimer’s Disease impacts nearly seven million people in the U.S., per the Alzheimer’s Association 2024 Facts and Figures report. About one in nine people above the age of 65 suffers from the disease — a number that’s expected to increase as time goes on and cost the nation billions yearly.

“I’m really happy and very pleased to have received this nomination,” Lopez said Thursday.

Advertise with us

The board of directors meets monthly and oversees all Alzheimer’s Association activities, its mission and the future of the nonprofit. He said he plans to maintain his responsibilities with the University of Pittsburgh and on the medical and scientific advisory board: “I’m going to try to do everything.”

Lopez said he is especially equipped to hold the position because of his long history and dedication to studying the disease.

“I have been studying Alzheimer’s disease for three decades, and I have conducted research studies in other countries,” he said. “I have an overall view of what’s going on from an international perspective.”

In addition to his appointments at the university, Lopez also sees dementia patients as a neurologist. This gives him a comprehensive perspective on the disease, said Sarah Berman, director of clinical core at the Alzheimer's Disease Research Center, a professor of neurology and clinical and translational science, and a neurologist herself who has worked closely with Lopez for decades.

“He’s a great choice because he’s had a long history of involvement in working in Alzheimer’s research,” she said. “He’s worked to understand the risk factors of the disease, and he’s influenced the field in significant ways.”

Advertise with us

Those contributions include his work on how changes to the brain’s small blood vessels can predispose someone to develop Alzheimer’s. Smoking and having high blood pressure are two ways we can influence changes on our brain’s vasculature.

Lopez also helped conduct some of the first experiments where researchers imaged amyloid plaques using a chemical called Pittsburgh Compound B — and when the plaques were linked to mild cognitive impairment.

“Pittsburgh is at the forefront of research in Alzheimer’s disease,” he said. “It has contributed significantly to research."

This work informs his role with the BRiTE program, where patients with the disease or related dementias are encouraged to exercise, work on brain puzzles or participate in other activities that researchers know protect the brain from neurodegeneration based on the literature.

Juleen Rodakowski saw just how involved Lopez was at BRiTE.

Advertise with us

She is chair of the occupational therapy department at the Pitt School of Health and Rehabilitation Sciences, as well as a researcher who studies the daily lives of people with Alzheimer’s disease and dementia. Rodakowski helped Lopez open the BRiTE program in 2016 and said she was mentored by him for over a decade.

She called him “a prolific scientist.”

“I greatly admire that he’s always focused on the patient’s wellbeing, even though his scientific work is very rigorous,” she said. “He has a broad understanding of the evidence of how to improve the lives of people with cognitive impairment.”

That’s because he’s not a “behind-the-scenes person,” said Rodakowski. “He’s always willing to meet families and to be a person in the room to ensure that patients have the best experience they can.”

Lopez said he’s optimistic about where the field is headed. The Food and Drug Administration has approved two drugs to treat the disease — lecanemab (Leqembi), by the pharmaceutical companies Eisai and Biogen, and donanemab (Kisunla), by Eli Lilly — which have been shown to reduce plaques that have been linked to brain degeneration.

“We are going into a very, very interesting phase for dementia and Alzheimer’s,” he said. “For the first time ever, we can say we can alter the pathology of the disease. This is huge.”